Autoimmune haemolytic anaemia represents a complex hematologic disorder characterized by pathological autoantibody-mediated red blood cell destruction. Clinical manifestations vary widely, ranging from mild indolent hemolysis to rapid life-threatening tissue hypoxia with high mortality. The recent AustrAIHANZ consensus guidelines establish a practical framework to address existing evidentiary gaps in diagnosis, therapy selection, and specialized patient management.

Diagnostic Approach to Autoimmune Haemolytic Anaemia

Accurate identification of autoimmune haemolytic anaemia demands rapid clinical suspicion alongside rigorous laboratory confirmation. Clinicians must establish active hemolysis by measuring elevated serum lactate dehydrogenase, reticulocyte counts, and unconjugated bilirubin while confirming depleted haptoglobin levels. Furthermore, a thorough examination of the peripheral blood smear remains essential to detect prominent spherocytes or agglutination patterns. Following initial confirmation, clinicians should perform a monospecific direct antiglobulin test to identify the specific class of causative immunoglobulins and complement components. This differentiation between warm-reactive immunoglobulin G and cold-reactive immunoglobulin M or complement proteins fundamentally determines subsequent clinical interventions. Additionally, physicians should investigate underlying secondary etiologies across all confirmed presentations. These secondary investigations encompass detailed evaluations for systemic lupus erythematosus, underlying lymphoproliferative malignancies, chronic viral infections, and recent pharmacological exposures. Consequently, identifying an associated systemic condition ensures that clinicians address the true primary driver of the hemolytic process. Early diagnostic precision therefore prevents therapeutic delays, minimizes organ ischemic complications, and guides targeted therapeutic selection before severe tissue hypoxia develops. Moreover, laboratories must perform extended serological testing when initial antiglobulin panels yield ambiguous or discordant results in severely compromised individuals.

First-Line Management Strategies and Glucocorticoid Protocols

Initial management of warm antibody autoimmune hemolytic disease focuses on prompt immunosuppression to halt accelerated extravascular erythrocyte clearance. Therefore, systemic glucocorticoids remain the cornerstone of first-line therapy for the majority of presenting adult patients. Clinicians typically initiate oral prednisone or prednisolone at doses of one milligram per kilogram daily. In fulminant presentations with rapid hemoglobin drops, intravenous methylprednisolone pulse therapy offers rapid stabilization. However, medical teams must closely monitor early response kinetics through serial hemoglobin evaluations, reticulocyte counts, and biochemical hemolysis markers. Once clinicians achieve stable hematologic remission, they should execute a gradual, vigilant steroid taper over several months. Rapid steroid tapering frequently triggers disease relapse and exposes patients to unnecessary cumulative steroid toxicity. Furthermore, clinicians must proactively institute supportive measures to counteract anticipated steroid-related adverse events. These measures include early bone protection against osteoporosis, blood glucose surveillance, and appropriate gastrointestinal prophylaxis. In contrast, patients exhibiting primary cold agglutinin disease rarely respond favorably to systemic corticosteroids. Consequently, physicians must avoid prolonged steroid courses in cold antibody disorders and focus instead on thermal protection and targeted monoclonal therapies. Clinicians must promptly transition refractory patients toward definitive second-line options without prolonged delay.

Second-Line Therapies and Targeted Immunosuppression

When patients demonstrate corticosteroid resistance, steroid dependence, or early disease relapse, clinicians must consider second-line interventions without undue delay. Rituximab represents the preferred second-line therapeutic option across contemporary clinical guidelines for warm autoimmune hemolysis. This anti-CD20 monoclonal antibody selectively depletes pathogenic B-cell populations, thereby reducing aberrant autoantibody synthesis and attenuating red cell clearance. Furthermore, clinicians can administer rituximab using either the conventional lymphoma dosing schedule or fixed-dose low-dose regimens with comparable efficacy. If monoclonal antibody therapy fails or remains unavailable, physicians may evaluate alternative immunosuppressive agents such as azathioprine, mycophenolate mofetil, or cyclosporine. Additionally, surgical splenectomy serves as a viable consideration for carefully selected patients with durable steroid dependency and warm autoantibodies. However, splenectomy carries persistent risks of perioperative morbidity, arterial and venous thrombosis, and severe encapsulated bacterial infections. Therefore, all surgical candidates require timely preoperative immunizations against pneumococcal, meningococcal, and Haemophilus influenzae infections. For patients confronting cold agglutinin syndromes, chemoimmunotherapy incorporating rituximab combined with bendamustine provides meaningful therapeutic responses, whereas surgical splenectomy typically proves ineffective because hepatic complement clearance predominates. Consequently, clinicians should individualize second-line therapy based on antibody class, patient comorbidities, and infectious risk profiles.

Transfusion Strategies and Supportive Care Considerations

Transfusion management in severe autoimmune hemolysis presents formidable serological and logistical challenges for healthcare providers. Broadly reactive autoantibodies routinely cause pan-agglutination, which masks underlying clinically significant alloantibodies during routine blood bank crossmatching. However, severe symptomatic anemia with end-organ ischemia constitutes an absolute indication for red cell transfusion that clinicians must never withhold. In emergency scenarios, transfusion services should issue the most compatible ABO- and Rh-matched red blood cells without waiting for complete resolution of autoantibody interference. Furthermore, clinicians must administer transfusions slowly under rigorous hemodynamic observation to identify acute adverse reactions early. Beyond urgent transfusions, comprehensive supportive care remains vital to patient survival and overall clinical recovery. Active intravascular and extravascular hemolysis generates high thrombotic potential due to circulating cell-free hemoglobin, microparticles, and localized inflammatory cascades. Consequently, clinicians must promptly initiate pharmacological venous thromboembolism prophylaxis with low-molecular-weight heparin unless severe active hemorrhage coexists. Additionally, patients undergoing accelerated erythropoiesis require continuous folic acid supplementation to prevent secondary megaloblastic arrest. Clinicians must maintain heightened vigilance for infectious complications resulting from profound immunosuppressive regimens. Therefore, routine infection surveillance, screening for opportunistic pathogens, and rapid fever management remain paramount throughout treatment.

Special Considerations in Pregnancy and Refractory Hemolysis

Managing autoimmune hemolysis during pregnancy requires meticulous multidisciplinary collaboration between hematologists, obstetricians, and maternal-fetal medicine specialists. Severe maternal anemia impairs adequate fetal oxygenation, increasing risks of intrauterine growth restriction, premature delivery, and perinatal loss. Furthermore, certain maternal autoantibodies, particularly warm immunoglobulin G molecules, cross the placental barrier and can trigger fetal or neonatal hemolysis. Glucocorticoids remain the primary therapeutic choice during pregnancy, although clinicians must balance maternal hyperglycemia, gestational hypertension, and premature rupture of membranes. In refractory gestational cases, intravenous immunoglobulin offers an acceptable temporizing option with minimal fetal toxicity. Conversely, clinicians should exercise extreme caution with cytotoxic agents and novel biologics during organogenesis. Beyond pregnancy, ultra-refractory adult cases with fulminant hemolysis require emergency rescue maneuvers within critical care environments. Clinicians may deploy plasma exchange to clear circulating antibodies or free hemoglobin transiently, alongside high-dose intravenous immunoglobulins. Emerging complement inhibitors and spleen tyrosine kinase inhibitors also offer promising salvage avenues for patients failing conventional pathways. Consequently, early referral to specialized tertiary hematology centers remains crucial for navigating complex refractory presentations successfully. Overall, coordinated multidisciplinary care ensures optimal maternal and fetal outcomes while preserving crucial therapeutic options.

Frequently Asked Questions

What diagnostic tests are required to confirm autoimmune haemolytic anaemia?

Clinicians confirm autoimmune haemolytic anaemia by documenting accelerated red cell breakdown alongside immune serological markers. Essential baseline investigations include complete blood counts, reticulocyte counts, serum lactate dehydrogenase, indirect bilirubin, and haptoglobin. A peripheral blood film typically reveals spherocytes or erythrocyte agglutination. Furthermore, clinicians must perform a monospecific direct antiglobulin test to identify specific red cell autoantibodies and complement binding, while evaluating potential underlying secondary conditions like lupus, viral infections, or lymphoproliferative disorders.

When should clinicians consider second-line therapies for warm autoimmune hemolytic disease?

Clinicians should consider second-line therapies whenever patients fail to achieve adequate hematologic stabilization on first-line corticosteroids. Additionally, secondary interventions are necessary if disease flares occur during steroid weaning or if sustained remission requires unacceptable maintenance doses of prednisolone. The preferred second-line agent is the anti-CD20 monoclonal antibody rituximab, which targets pathogenic autoantibody production. Alternative options include conventional steroid-sparing immunosuppressive medications or surgical splenectomy for carefully selected candidates after considering infection and thrombosis risks.

Is red blood cell transfusion safe in patients with acute autoimmune haemolytic anaemia?

Blood transfusion is safe and potentially life-saving in acute autoimmune haemolytic anaemia when patients suffer from severe symptomatic hypoxia or tissue ischemia. Although autoantibodies frequently complicate crossmatching and cause pan-agglutination, blood banks can identify the most compatible units available. Transfusions should never be withheld in life-threatening circumstances due to compatibility delays. Healthcare teams must administer blood products slowly under intensive bedside monitoring while simultaneously delivering high-dose corticosteroids or emergent rescue immunosuppressive therapies.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Choi P et al. AustrAIHANZ - consensus guidelines on the investigation and management of autoimmune haemolytic anaemia in Australia and New Zealand. Intern Med J. 2026 Nov 08. doi: 10.1111/imj.70656. PMID: 43000214.
2. Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev. 2020;41:100648.
3. Berentsen S, Barcellini W. Autoimmune hemolytic anemias. N Engl J Med. 2021;385(15):1407-1419.